Pet Drug Reports

Ingredients

Active ingredient · pooled across combinations

Selamectin: adverse event reports, pooled

3 ingredient sets in reports · 7 FDA-approved applications in the Green Book

71,504reports naming the ingredient, 1999–20265.3% of all reports · about 2,657 a year
2,170reports, 12 months to March 20262,260 in the 12 months before
22.9%classed serious, as reportedall reports: 38.6%
41.6%of reports concern catsdog 41.1%

71,504 adverse event reports received by FDA list a drug containing selamectin, alone or in combination, from May 1999 to March 2026. This page pools every ingredient set that includes it; 3 such sets appear in reports.

The Green Book lists 7 FDA-approved applications containing it. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

2,170 reports arrived in the 12 months to March 2026, close to the 2,260 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. That is about 2,657 reports a year over its reporting history and 5.3% of all reports.

Pooled across every set, the terms listed most often are ineffective, heartworm larvae (11.4%), application site alopecia (9%) and lack of efficacy (ectoparasite) - flea (8.8%). Many drugs combine several ingredients, and many reports list several drugs, so a term on this page may relate to any of them or to none.

Of reports that state seriousness, 22.9% were classed as serious (38.6% across the whole database); 3.3% record a death or euthanasia (6.4% overall). Ingredients used in older or sicker animals, or in anaesthesia and cancer care, carry higher shares for that reason alone.

Ingredient sets that include selamectin

Active ingredients recorded for the drugReportsShare of this page's reportsLatest 12 months
Selamectin62,14586.9%841
Sarolaner + Selamectin9,46613.2%1,333
Eprinomectin + Praziquantel + Selamectin10%0

Ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another"; counts follow sales volume and years on the market. A report can list more than one set, so shares can add to more than 100%.

Signs listed in reports, pooled

share of selamectin reports listing the termall reports in the database

  1. Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]11.4%8,169
  2. Application site alopecia[hair loss where the product was applied]9%6,462
  3. Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]8.8%6,307
  4. Vomiting8%5,741
  5. Underfilling, Tubes[a product quality report, not a sign in an animal]6.5%4,635
  6. Application site hair loss[hair loss where the product was applied]6.3%4,532
  7. Anorexia[not eating]5.2%3,699
  8. Depression[dull, quiet or withdrawn]5%3,587
  9. Lethargy[unusually tired or inactive]4.9%3,496
  10. Diarrhoea[diarrhea]4.2%2,993
  11. Pruritus[itching]3.6%2,581
  12. Accidental exposure[exposure that was not intended]3.2%2,280
  13. Tubes, Leaking[a product quality report, not a sign in an animal]3.1%2,192
  14. Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]2.5%1,812
  15. Application site lesion[lesion where the product was applied]2.3%1,652
  16. Unclassifiable adverse event[event that fits no dictionary term]2.2%1,602
  17. Ataxia[unsteady, uncoordinated movement]2.2%1,598
  18. Behavioural disorder NOS[behaviour change, type not specified]2.1%1,516
  19. Application site scab[scab where the product was applied]2.1%1,493
  20. Death2.1%1,489
  21. Application site erythema[reddened skin where the product was applied]2.1%1,488
  22. Lack of efficacy (ectoparasite) - ear mite[the product did not have the expected effect: ear mites]2%1,427
  23. Lack of efficacy (ectoparasite) - tick NOS[the product did not have the expected effect: ticks]2%1,417
  24. Lack of efficacy - NOS[the product did not have the expected effect]1.8%1,281
  25. Fever1.8%1,265
  26. Tubes, Abnormal[a product quality report, not a sign in an animal]1.8%1,253
  27. No sign[no clinical sign was reported]1.7%1,199
  28. Application site inflammation[inflammation where the product was applied]1.7%1,192
  29. Application site pruritus[itching where the product was applied]1.6%1,150
  30. Ineffective, ascarids NOS[legacy FDA term: the product did not have the expected effect (ascarids nos)]1.6%1,109

Pooled across every ingredient set and every report that names the ingredient. One report can list several terms and several drugs; a term here may relate to any of them or to none.

Monthly reports by species, five years

Dog1,896 · peak 61
Apr 2021: 36May 2021: 37Jun 2021: 44Jul 2021: 43Aug 2021: 45Sep 2021: 36Oct 2021: 40Nov 2021: 36Dec 2021: 28Jan 2022: 26Feb 2022: 24Mar 2022: 29Apr 2022: 29May 2022: 61Jun 2022: 46Jul 2022: 38Aug 2022: 47Sep 2022: 34Oct 2022: 34Nov 2022: 20Dec 2022: 24Jan 2023: 22Feb 2023: 16Mar 2023: 22Apr 2023: 37May 2023: 38Jun 2023: 42Jul 2023: 34Aug 2023: 33Sep 2023: 23Oct 2023: 42Nov 2023: 29Dec 2023: 17Jan 2024: 14Feb 2024: 8Mar 2024: 29Apr 2024: 34May 2024: 30Jun 2024: 40Jul 2024: 32Aug 2024: 47Sep 2024: 38Oct 2024: 26Nov 2024: 26Dec 2024: 23Jan 2025: 15Feb 2025: 20Mar 2025: 24Apr 2025: 34May 2025: 43Jun 2025: 45Jul 2025: 37Aug 2025: 36Sep 2025: 34Oct 2025: 30Nov 2025: 32Dec 2025: 30Jan 2026: 19Feb 2026: 20Mar 2026: 182022202320242025
Cat7,338 · peak 172
Apr 2021: 142May 2021: 126Jun 2021: 172Jul 2021: 157Aug 2021: 143Sep 2021: 140Oct 2021: 134Nov 2021: 118Dec 2021: 97Jan 2022: 79Feb 2022: 86Mar 2022: 124Apr 2022: 106May 2022: 120Jun 2022: 85Jul 2022: 128Aug 2022: 121Sep 2022: 122Oct 2022: 122Nov 2022: 94Dec 2022: 80Jan 2023: 102Feb 2023: 90Mar 2023: 102Apr 2023: 117May 2023: 158Jun 2023: 146Jul 2023: 156Aug 2023: 166Sep 2023: 130Oct 2023: 132Nov 2023: 129Dec 2023: 88Jan 2024: 84Feb 2024: 105Mar 2024: 107Apr 2024: 108May 2024: 148Jun 2024: 163Jul 2024: 147Aug 2024: 133Sep 2024: 132Oct 2024: 160Nov 2024: 152Dec 2024: 110Jan 2025: 105Feb 2025: 90Mar 2025: 104Apr 2025: 116May 2025: 160Jun 2025: 143Jul 2025: 139Aug 2025: 139Sep 2025: 134Oct 2025: 167Nov 2025: 106Dec 2025: 105Jan 2026: 89Feb 2026: 90Mar 2026: 902022202320242025
Horse0 · peak 1
2022202320242025
Other2,041 · peak 57
Apr 2021: 46May 2021: 48Jun 2021: 49Jul 2021: 51Aug 2021: 57Sep 2021: 56Oct 2021: 50Nov 2021: 48Dec 2021: 42Jan 2022: 41Feb 2022: 35Mar 2022: 40Apr 2022: 50May 2022: 51Jun 2022: 37Jul 2022: 44Aug 2022: 52Sep 2022: 35Oct 2022: 21Nov 2022: 24Dec 2022: 24Jan 2023: 34Feb 2023: 26Mar 2023: 24Apr 2023: 39May 2023: 35Jun 2023: 30Jul 2023: 42Aug 2023: 44Sep 2023: 35Oct 2023: 29Nov 2023: 30Dec 2023: 25Jan 2024: 30Feb 2024: 27Mar 2024: 23Apr 2024: 24May 2024: 29Jun 2024: 29Jul 2024: 47Aug 2024: 50Sep 2024: 27Oct 2024: 36Nov 2024: 28Dec 2024: 19Jan 2025: 25Feb 2025: 18Mar 2025: 21Apr 2025: 29May 2025: 32Jun 2025: 36Jul 2025: 24Aug 2025: 27Sep 2025: 34Oct 2025: 30Nov 2025: 24Dec 2025: 18Jan 2026: 21Feb 2026: 16Mar 2026: 232022202320242025

By month of receipt; each panel has its own scale. The newest months are incomplete because FDA posts reports with a delay of three to six months.

02,8685,7361999: 17919992000: 5,7362001: 4,7722002: 3,51420022003: 1,4882004: 2,0602005: 2,20320052006: 2,4032007: 2,8032008: 2,77820082009: 2,8772010: 2,8042011: 2,50020112012: 2,7162013: 2,7372014: 2,54320142015: 2,5552016: 2,6962017: 2,57320172018: 2,2472019: 2,8412020: 2,68720202021: 2,5382022: 2,1332023: 2,26420232024: 2,2652025: 2,2062026: 3862026

Outcomes, report types and ages

Outcome recorded in the report

Recovered/Normal6%4,279
Recovered with Sequela0%32
Ongoing17.8%12,692
Died2.8%1,978
Euthanized0.5%351
Outcome Unknown17.4%12,442

What kind of report it was

Safety issue72.1%51,575
Lack of expected effectiveness10%7,118
Both safety and lack of expected effectiveness4%2,865
Manufacturing or product defect13.8%9,899
Other0.1%47

Species

Cat41.6%29,764
Dog41.1%29,419
Human exposure3.2%2,303
Other0.4%294
Rabbit0.1%103
Ferret0.1%36

Age of the animal

Under 1 year12%8,567
1 to 3 years24%17,189
4 to 7 years19.5%13,952
8 to 11 years11.9%8,500
12 years and over8.2%5,880
Age not given24.4%17,416

Coloured bar: reports naming selamectin. Grey bar: all 1,357,245 reports. Outcomes are as stated by the reporter; FDA has not necessarily determined whether any product played a part.

In context

MeasureSelamectinAll reports
Reports71,5041,357,245
Latest 12 months against the 12 before-4%-5%
Classed serious, of reports stating it22.9%38.6%
Death or euthanasia recorded, per 1,000 reports32.563.8
Filed as lack of expected effectiveness (wholly or partly)14%23%

Shares of reports, not of animals treated: how many animals receive the ingredient is not public. Ingredients used in anaesthesia, cancer care or in old animals carry more serious outcomes in their reports for that reason alone.

FDA-approved products containing selamectin (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 30 Sep 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
RevolutionSelamectinZoetis Inc.Dogs, CatsNADA 141-152
Revolution PlusSarolaner, SelamectinZoetis Inc.CatsNADA 141-502
SelaridSelamectinNorbrook Laboratories, Ltd.Dogs, CatsANADA 200-663
SenergySelamectinVirbac AH, Inc.Dogs, CatsANADA 200-670
RevoltSelamectinAurora Pharmaceutical, Inc.Dogs, CatsANADA 200-673
SelaSpotSelamectinBimeda Animal Health Ltd.Dogs, CatsANADA 200-696
SelamectinSelamectinZyVet Animal Health, Inc.Dogs, CatsANADA 200-769

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about selamectin reports

How many FDA adverse event reports mention selamectin?

71,504 reports through March 2026, 2,170 of them in the latest 12 months, counting selamectin alone and in combinations.

Which brands do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book reference list on this page names approved products containing selamectin without any counts.

In which combinations is selamectin reported?

Selamectin (86.9% of these reports), Sarolaner + Selamectin (13.2% of these reports) and Eprinomectin + Praziquantel + Selamectin (0% of these reports).

What reactions are reported for selamectin?

ineffective, heartworm larvae (11.4%), application site alopecia (9%), lack of efficacy (ectoparasite) - flea (8.8%), vomiting (8%) and underfilling, Tubes (6.5%). Shares are of reports naming the ingredient; one report can list several terms.

Which animals are these reports about?

cat (41.6%), dog (41.1%) and human exposure (3.2%).

Does a high count mean selamectin is a problem ingredient?

A count cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." Widely used ingredients collect more reports because more animals receive them.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Ingredient names follow the Green Book; salts and forms are kept as FDA lists them. Drug entries are matched by the active ingredients their unmasked ingredient field discloses. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.